These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 37759815)

  • 1. Chirality Matters: Fine-Tuning of Novel Monoamine Reuptake Inhibitors Selectivity through Manipulation of Stereochemistry.
    Kalaba P; Pacher K; Neill PJ; Dragacevic V; Zehl M; Wackerlig J; Kirchhofer M; Sartori SB; Gstach H; Kouhnavardi S; Fabisikova A; Pillwein M; Monje-Quiroga F; Ebner K; Prado-Roller A; Singewald N; Urban E; Langer T; Pifl C; Lubec J; Leban JJ; Lubec G
    Biomolecules; 2023 Sep; 13(9):. PubMed ID: 37759815
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Further structure-activity relationship studies of piperidine-based monoamine transporter inhibitors: effects of piperidine ring stereochemistry on potency. Identification of norepinephrine transporter selective ligands and broad-spectrum transporter inhibitors.
    He R; Kurome T; Giberson KM; Johnson KM; Kozikowski AP
    J Med Chem; 2005 Dec; 48(25):7970-9. PubMed ID: 16335921
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel conformationally constrained tropane analogues by 6-endo-trig radical cyclization and stille coupling - switch of activity toward the serotonin and/or norepinephrine transporter.
    Hoepping A; Johnson KM; George C; Flippen-Anderson J; Kozikowski AP
    J Med Chem; 2000 May; 43(10):2064-71. PubMed ID: 10821718
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biaryl analogues of conformationally constrained tricyclic tropanes as potent and selective norepinephrine reuptake inhibitors: synthesis and evaluation of their uptake inhibition at monoamine transporter sites.
    Zhou J; Zhang A; Kläss T; Johnson KM; Wang CZ; Ye YP; Kozikowski AP
    J Med Chem; 2003 May; 46(10):1997-2007. PubMed ID: 12723962
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structure-Activity Relationships of Novel Thiazole-Based Modafinil Analogues Acting at Monoamine Transporters.
    Kalaba P; Ilić M; Aher NY; Dragačević V; Wieder M; Zehl M; Wackerlig J; Beyl S; Sartori SB; Ebner K; Roller A; Lukic N; Beryozkina T; Gonzalez ERP; Neill P; Khan JA; Bakulev V; Leban JJ; Hering S; Pifl C; Singewald N; Lubec J; Urban E; Sitte HH; Langer T; Lubec G
    J Med Chem; 2020 Jan; 63(1):391-417. PubMed ID: 31841637
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structure-activity relationships at monoamine transporters and muscarinic receptors for N-substituted-3alpha-(3'-chloro-, 4'-chloro-, and 4',4''-dichloro-substituted-diphenyl)methoxytropanes.
    Newman AH; Robarge MJ; Howard IM; Wittkopp SL; George C; Kopajtic T; Izenwasser S; Katz JL
    J Med Chem; 2001 Feb; 44(4):633-40. PubMed ID: 11170654
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Further SAR studies of piperidine-based analogues of cocaine. 2. Potent dopamine and serotonin reuptake inhibitors.
    Tamiz AP; Zhang J; Flippen-Anderson JL; Zhang M; Johnson KM; Deschaux O; Tella S; Kozikowski AP
    J Med Chem; 2000 Mar; 43(6):1215-22. PubMed ID: 10737754
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel Potent Dopamine-Norepinephrine and Triple Reuptake Uptake Inhibitors Based on Asymmetric Pyran Template and Their Molecular Interactions with Monoamine Transporters.
    Santra S; Kortagere S; Vedachalam S; Gogoi S; Antonio T; Reith MEA; Dutta AK
    ACS Chem Neurosci; 2021 Apr; 12(8):1406-1418. PubMed ID: 33844493
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacological and behavioral characterization of D-473, an orally active triple reuptake inhibitor targeting dopamine, serotonin and norepinephrine transporters.
    Dutta AK; Santra S; Sharma H; Voshavar C; Xu L; Mabrouk O; Antonio T; Reith ME
    PLoS One; 2014; 9(11):e113420. PubMed ID: 25427177
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relative contributions of norepinephrine and serotonin transporters to antinociceptive synergy between monoamine reuptake inhibitors and morphine in the rat formalin model.
    Shen F; Tsuruda PR; Smith JA; Obedencio GP; Martin WJ
    PLoS One; 2013; 8(9):e74891. PubMed ID: 24098676
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacological and behavioral analysis of the effects of some bivalent ligand-based monoamine reuptake inhibitors.
    Tamiz AP; Bandyopadhyay BC; Zhang J; Flippen-Anderson JL; Zhang M; Wang CZ; Johnson KM; Tella S; Kozikowski AP
    J Med Chem; 2001 May; 44(10):1615-22. PubMed ID: 11334571
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Slow-onset, long-duration 3-(3',4'-dichlorophenyl)-1-indanamine monoamine reuptake blockers as potential medications to treat cocaine abuse.
    Froimowitz M; Wu KM; Moussa A; Haidar RM; Jurayj J; George C; Gardner EL
    J Med Chem; 2000 Dec; 43(26):4981-92. PubMed ID: 11150168
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Further studies on conformationally constrained tricyclic tropane analogues and their uptake inhibition at monoamine transporter sites: synthesis of (Z)-9-(substituted arylmethylene)-7-azatricyclo[4.3.1.0(3,7)]decanes as a novel class of serotonin transporter inhibitors.
    Zhang A; Zhou G; Hoepping A; Mukhopadhyaya J; Johnson KM; Zhang M; Kozikowski AP
    J Med Chem; 2002 Apr; 45(9):1930-41. PubMed ID: 11960503
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery and Development of Monoamine Transporter Ligands.
    Aggarwal S; Mortensen OV
    Adv Neurobiol; 2023; 30():101-129. PubMed ID: 36928847
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Emerging structure-function relationships defining monoamine NSS transporter substrate and ligand affinity.
    Wang CI; Lewis RJ
    Biochem Pharmacol; 2010 Apr; 79(8):1083-91. PubMed ID: 19954741
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Further structural exploration of trisubstituted asymmetric pyran derivatives (2S,4R,5R)-2-benzhydryl-5-benzylamino-tetrahydropyran-4-ol and their corresponding disubstituted (3S,6S) pyran derivatives: a proposed pharmacophore model for high-affinity interaction with the dopamine, serotonin, and norepinephrine transporters.
    Zhang S; Fernandez F; Hazeldine S; Deschamps J; Zhen J; Reith ME; Dutta AK
    J Med Chem; 2006 Jul; 49(14):4239-47. PubMed ID: 16821783
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Coordination of Na(+) by monoamine ligands in dopamine, norepinephrine, and serotonin transporters.
    Xhaard H; Backström V; Denessiouk K; Johnson MS
    J Chem Inf Model; 2008 Jul; 48(7):1423-37. PubMed ID: 18543980
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recent advances in the understanding of the interaction of antidepressant drugs with serotonin and norepinephrine transporters.
    Andersen J; Kristensen AS; Bang-Andersen B; Strømgaard K
    Chem Commun (Camb); 2009 Jul; (25):3677-92. PubMed ID: 19557250
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of potent dopamine-norepinephrine uptake inhibitors (DNRIs) based on a (2S,4R,5R)-2-benzhydryl-5-((4-methoxybenzyl)amino)tetrahydro-2H-pyran-4-ol molecular template.
    Santra S; Sharma H; Vedachalam S; Antonio T; Reith M; Dutta A
    Bioorg Med Chem; 2015 Feb; 23(4):821-8. PubMed ID: 25593099
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis and biological evaluation of novel 3,4-diaryl lactam derivatives as triple reuptake inhibitors.
    Park JE; Song C; Choi K; Sim T; Moon B; Roh EJ
    Bioorg Med Chem Lett; 2013 Oct; 23(20):5515-8. PubMed ID: 24012181
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.